Data Supplement from IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers

Pierfrancesco Marra(King's College London), Andrew Tutt(Institute of Cancer Research), Sonya Hessey(Royal London Hospital), Anita Grigoriadis(London Cancer), Emanuele de Rinaldis(Target (United States)), Fernanda Kyle‐Cezar(King's College London), Johnathan Watkins(King's College London), Adrian Hayday(The Francis Crick Institute), Yin Wu, Mamunur Rashid, Sumi Mathew(King's College London), Patrycja Gazińska(London Cancer)
Unknown
March 30, 2023
10.1158/0008-5472.22404048
Cited by 0

Related Papers

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Mutational Processes Molding the Genomes of 21 Breast Cancers
|Cell|2012|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k